<DOC>
	<DOC>NCT00016445</DOC>
	<brief_summary>OBJECTIVES: I. Determine the effect of growth hormone on height, height velocity, body weight, and lean body mass in patients with cystic fibrosis. II. Determine the effect of growth hormone on pulmonary function in these patients. III. Determine the impact of this drug on the quality of life in these patients. IV. Determine if the clinical response from this drug is sustained in these patients.</brief_summary>
	<brief_title>Phase II Study of Growth Hormone in Children With Cystic Fibrosis</brief_title>
	<detailed_description>PROTOCOL OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms. Arm I: Patients receive growth hormone subcutaneously (SC) daily for 1 year during the first year only. Arm II: Patients receive growth hormone SC daily for 1 year during the second year only. Quality of life is assessed at baseline and then every 6 months for 2 years.</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA: Disease Characteristics Diagnosis of prepubertal cystic fibrosis No colonization by Burkholderia cepacia Prior/Concurrent Therapy No prior or concurrent insulin requirement Patient Characteristics Hematopoietic: No hematologic disease Hepatic: No liver disease Renal: No kidney disease Pulmonary: Must be able to perform pulmonary function testing Other: No history of diabetes Must be less than 25% of normal height and/or weight for age and sex</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>cardiovascular and respiratory diseases</keyword>
	<keyword>cystic fibrosis</keyword>
	<keyword>disease-related problem/condition</keyword>
	<keyword>genetic diseases and dysmorphic syndromes</keyword>
	<keyword>quality of life</keyword>
	<keyword>rare disease</keyword>
</DOC>